AbbVie Gets FDA OK of Juvmo for Parkinson's Disease
AbbVie Inc ABBV
News
ADARx Pharmaceuticals to Sell 21.9 Million Shares at $15-$17 Each in IPO
AbbVie's Menstrual Migraine Treatment Meets Primary, Secondary Endpoints in Phase 3 Trial
Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.
AbbVie Says Blood Cancer Drug Met Dual Primary Endpoints in Phase 3 Study
Moderna's cancer-vaccine breakthrough drives broad biopharma stock rally
AbbVie Lowers Outlook to Account for Acquisition, as 2Q Profit Jumps
AbbVie Gets Europe OK for Rinvoq in Vitiligo, Alopecia Areata
Genmab, AbbVie Say Lymphoma Drug Failed to Meet Primary Endpoint in Phase 3 Trial
AbbVie Currently Down Seven Consecutive Days, On Pace for Longest Losing Streak Since March 2025 — Data Talk
Regenxbio Shares Rise on $100 Million Milestone Payment After First Patient Dosed in Eye-Disease Trial
AbbVie, Genmab's Lymphoma Treatment Meets Primary Endpoint in Phase 3 Trial
AbbVie Gets CHMP Backing for Rinvoq in Vitiligo, Alopecia Areata
AbbVie's Skyrizi Gets FDA Approval For Pediatric Use
Healthcare stocks have become a haven for investors ditching tech
AbbVie On Pace For Record Closing High — Data Talk
AbbVie Gets Expanded European Approvals for Skyrizi, Maviret
AbbVie is buying a biotech company working on an experimental eczema drug for $10.9 billion
AbbVie Up Nearly 7%, on Pace for Largest Percent Increase Since November 2020 — Data Talk
AbbVie on Pace for Largest Percent Increase Since October 2025 — Data Talk
United States